Dr. Robert Warnock DPh
Vice President of Pharmacy Services , Golden Clinical Services
Member of the Healthcare Council
Council Member Biography
Robert Warnock, DPh, CGP, FASCP is Vice President of Pharmacy Services at Golden Clinical Services in Fort Smith, AR, and is an Adjunct Assistant Professor of Geriatrics at Mercer University Southern School of Pharmacy in Atlanta, Georgia. He was previously Regional Clinical Director of the Southeastern Region at Omnicare in Covington, KY. He has been a member of the American Society of Consultant Pharmacists (ASCP) since 1984 and has served as president of the Georgia Chapter in addition to Secretary/Treasurer. He served as chair of the Organizational Affairs Council, and is a past member of the Professional Affairs Council and Government Affairs Committee. Dr. Warnock received his BS degree from the University of Georgia College of Pharmacy, and after completing his clinical externship rotations at the Medical College of Georgia in Augusta, he became a licensed pharmacist in Georgia and a licensed doctor of pharmacy in Tennessee. (This is me - Update Profile)
Employment History
- 2005 - Unspecified
- Vice President of Pharmacy Services , Golden Clinical Services
- 1996 - 2005
- Southeast Regional Clinical Director, OMNICARE, INC.
- 1987 - Unspecified
- Adjunct Assistant Professor of Pharmacy, Mercer University Southern School of Pharmacy
GLG NewsSM Analyses by Robert Warnock(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Medicare Prescription Drug Plan Unworkable in LTC
August 14, 2006
U.S. Seniors Navigating New Medicare Prescription Drug Plan: Some Beneficiaries Encounter Problems | www.medscape.com
The Med D Drug Program did not consider critical aspects of care for institutional elderly in LTC facilities. We have now seen the correction of many of the initial problems with the Med D program, but it remains a major burden for LTC pharmacies as well as SNF staff and physicians. CMS will need to step up and require that PDPs consider the special needs of the institutional elderly if they are to correct these problems and allow this program to work for these frail elderly recipients.
-
Zostavax - Future in CMS/CDC's Hands
August 2, 2006
FDA approves Zostavax, Merck's new vaccine for preventing shingles in adults 60 and older | www.therapeuticsdaily.com
Zoxtavax offers the first real answer for senior's who increasingly suffer with shingles, but the drugs future use or lack thereof is probably in the hands of the CDC/CMS.
-
Bausch & Lomb is Still a Name consumers count on
June 9, 2006
Bausch & Lomb Voluntarily Recalls MoistureLoc ® Worldwide | www.bausch.com
Bausch and Lomb's recent recall of MoistureLoc demonstrates the company's continued commitment to providing quality eye care products, regardless of the financial implications.
-
Novartis Heart Combo - Will PDP plans pay for combo?
June 9, 2006
Novartis Reports Two Heart Drugs Are Safe, Effective | online.wsj.com
I agree with previous authors about the potential benefit from the combination of valsartan and amlodipine. Both are well proven medications with clear advantages.
This combination will be most beneficial to patients with resistent hypertension, such as the diabetic patients mentioned in the previous assessment. Most of these target patients will be older long term hypertensive residents.
Therefore, one of the important question for Novartis may be whether or not these drugs will be covered by the new Medicare Part D prescription drug plans.
Leading institutions connect with Robert Warnock through GLG
GLG Study Groups with Robert Warnock(?)
| Study Group Name | No. Members |
|---|---|
| Pharmacists (US) | 2077 |
| Generic Drug Economic Experts | 766 |
| Medicare Experts | 493 |
| Nursing Home & Skilled Nursing Facility Experts | 193 |
| Experts on Generic Pharmaceuticals: Pharmacists | 106 |
GLG Live Meetings with Robert Warnock(?)
Robert Warnock has not participated in any GLG Live Meetings.